Literature DB >> 16490052

Correlation between regional myasthenic weakness and mental aspects of quality of life.

A Rostedt1, L Padua, E V Stålberg.   

Abstract

Here we report how the different types of regional muscle involvement, i.e. bulbar, ocular or generalized, in patients with myasthenia gravis (MG) influence the mental aspects of quality of life. Clinical examination according to Osserman was performed in 48 MG patients (45 women, three men; mean age 54, SD 12 years). Each patient was at the time for clinical evaluation asked to fill out the disease-specific Myasthenia Gravis Questionnaire (MGQ) and the Short-Form 36-item questionnaire for health survey (SF-36) as patient-oriented tools. We related the regional domains (generalized domain, bulbar domain and ocular domain) of the MGQ and the clinical findings, respectively, with mental quality of life as assessed by SF-36. Bulbar and generalized involvement results in impairment of mental aspects of quality of life, whereas ocular involvement does not.

Entities:  

Mesh:

Year:  2006        PMID: 16490052     DOI: 10.1111/j.1468-1331.2006.01149.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  13 in total

Review 1.  Diagnosis and management of autoimmune myasthenia gravis.

Authors:  Corrado Angelini
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

2.  Quality of life and life circumstances in German myasthenia gravis patients.

Authors:  Sabine Twork; Susanne Wiesmeth; Jörg Klewer; Dieter Pöhlau; Joachim Kugler
Journal:  Health Qual Life Outcomes       Date:  2010-11-11       Impact factor: 3.186

3.  Evaluation of a scale of patient-reported outcomes for the assessment of myasthenia gravis patients in China.

Authors:  Feng-bin Liu; Xin-lin Chen; Li Guo; Xiao-bin Liu
Journal:  Chin J Integr Med       Date:  2012-02-27       Impact factor: 1.978

4.  Health-related quality of life in ALS, myasthenia gravis and facioscapulohumeral muscular dystrophy.

Authors:  Yaroslav Winter; Karsten Schepelmann; Annika E Spottke; Detlef Claus; Christoph Grothe; Rolf Schröder; Dieter Heuss; Stefan Vielhaber; Björn Tackenberg; Veit Mylius; Jens-Peter Reese; Reinhard Kiefer; Bertold Schrank; Wolfgang H Oertel; Richard Dodel
Journal:  J Neurol       Date:  2010-04-10       Impact factor: 4.849

5.  Assessment of health-related quality of life in patients with myasthenia gravis in Belgrade (Serbia).

Authors:  Ivana Z Basta; Tatjana D Pekmezović; Stojan Z Perić; Darija B Kisić-Tepavčević; Vidosava M Rakočević-Stojanović; Zorica D Stević; Dragana V Lavrnić
Journal:  Neurol Sci       Date:  2012-08-09       Impact factor: 3.307

6.  The relationship between health, disability and quality of life in myasthenia gravis: results from an Italian study.

Authors:  Matilde Leonardi; Alberto Raggi; Carlo Antozzi; Paolo Confalonieri; Lorenzo Maggi; Ferdinando Cornelio; Renato Mantegazza
Journal:  J Neurol       Date:  2009-08-08       Impact factor: 4.849

7.  Factors correlating quality of life in patients with myasthenia gravis.

Authors:  Kongkiat Kulkantrakorn; Kittisak Sawanyawisuth; Somsak Tiamkao
Journal:  Neurol Sci       Date:  2010-05-12       Impact factor: 3.307

8.  Social support and self-efficacy in patients with Myasthenia Gravis: a common pathway towards positive health outcomes.

Authors:  Alberto Raggi; Matilde Leonardi; Renato Mantegazza; Silvia Casale; Giulia Fioravanti
Journal:  Neurol Sci       Date:  2010-04       Impact factor: 3.307

9.  Concordance between severity of disease, disability and health-related quality of life in myasthenia gravis.

Authors:  Alberto Raggi; Matilde Leonardi; Carlo Antozzi; Paolo Confalonieri; Lorenzo Maggi; Ferdinando Cornelio; Renato Mantegazza
Journal:  Neurol Sci       Date:  2009-10-09       Impact factor: 3.307

10.  Major motor-functional determinants associated with poor self-reported health-related quality of life in myasthenia gravis patients.

Authors:  David Cioncoloni; Stefania Casali; Federica Ginanneschi; Marisa Carone; Boni Veronica; Alessandro Rossi; Fabio Giannini
Journal:  Neurol Sci       Date:  2016-04-01       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.